Analysts Anticipate Oramed Pharmaceuticals Inc. (ORMP) Will Announce Quarterly Sales of $610,000.00

Wall Street brokerages expect that Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) will announce $610,000.00 in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Oramed Pharmaceuticals’ earnings, with the highest sales estimate coming in at $620,000.00 and the lowest estimate coming in at $600,000.00. Oramed Pharmaceuticals posted sales of -$930,000.00 in the same quarter last year, which suggests a positive year over year growth rate of 165.6%. The firm is scheduled to announce its next earnings report on Friday, November 24th.

On average, analysts expect that Oramed Pharmaceuticals will report full year sales of $610,000.00 for the current financial year, with estimates ranging from $2.44 million to $2.46 million. For the next fiscal year, analysts expect that the firm will report sales of $2.40 million per share, with estimates ranging from $2.00 million to $2.80 million. Zacks’ sales averages are an average based on a survey of analysts that that provide coverage for Oramed Pharmaceuticals.

Several research analysts have weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $25.00 price objective on shares of Oramed Pharmaceuticals in a research report on Thursday, October 5th. ValuEngine upgraded Oramed Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, September 6th.

COPYRIGHT VIOLATION NOTICE: “Analysts Anticipate Oramed Pharmaceuticals Inc. (ORMP) Will Announce Quarterly Sales of $610,000.00” was reported by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this news story can be read at

An institutional investor recently raised its position in Oramed Pharmaceuticals stock. Wells Fargo & Company MN boosted its holdings in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) by 4.4% during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 14,725 shares of the biotechnology company’s stock after acquiring an additional 625 shares during the quarter. Wells Fargo & Company MN owned 0.11% of Oramed Pharmaceuticals worth $114,000 at the end of the most recent reporting period. 1.27% of the stock is currently owned by institutional investors.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection.

Get a free copy of the Zacks research report on Oramed Pharmaceuticals (ORMP)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Oramed Pharmaceuticals (NASDAQ:ORMP)

What are top analysts saying about Oramed Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Oramed Pharmaceuticals Inc. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit